| Budget Amount *help |
¥17,420,000 (Direct Cost: ¥13,400,000、Indirect Cost: ¥4,020,000)
Fiscal Year 2015: ¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2014: ¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2013: ¥9,230,000 (Direct Cost: ¥7,100,000、Indirect Cost: ¥2,130,000)
|
|---|
| Outline of Final Research Achievements |
Inactivated Sendai virus (hemagglutinating virus of Japan; HVJ) envelope (HVJ-E) with anti-tumor activities were incorporated into mouse platelets.The hemagglutination activity which disturbs systemic administration of HVJ-E was dramatically attenuated by incorporation into platelets. Then, platelets incorporating HVJ-E (PH complex) were injected into the tail veins of B16F10 melanoma-bearing mice. The PH complex dominantly accumulated in tumor tissues and significantly suppressed melanoma growth in mice. Lung metastasis was also suppressed by susyemic administration of PH complex. Chemokine, IP-10, was also incorporated into platelet vector. The IP-10/platelet also suppressed melanoma growth in mic by systemic administration. Thus, the platelet vector incorporating anti-tumor reagents will provide a new approach for cancer-targeting therapy using oncolytic viruses.
|
